It's How Medicine Should Be®
<< Previous | New Search | Return to Search Results | Next >>

Physician Profile


call (888) 352-RUSH for help arranging an appointment

Kathleen M. Shannon, MD

Patient Feedback
  • Neurology
Board Certification:
  • Neurology
Faculty Rank: Professor
Medical or Graduate Education: Rush Medical College
Residency: Rush University Medical Center - Neurology
Fellowship: Rush University Medical Center - Movement Disorders
Clinical Expertise:
  • Botulinum toxin injections
  • Chorea
  • Corticobasal degeneration
  • Dystonia
  • Hemifacial spasm
  • Huntington's disease
  • Movement disorders
  • Multiple system atrophy
  • Parkinson's disease
  • Parkinsonism
  • Progressive supranuclear palsy
  • Restless legs syndrome (RLS)
  • Stiff-person syndrome
  • Tics
  • Wilson disease
  • Writer's cramp
Research Interests:
  • Clinical trials in Parkinson's disease
  • Clinical trials in Huntington disease
  • Clinical trials in dystonia
  • Dystonia
  • Parkinson's disease
  • Genetics and movement disorders
  • Pharmacological studies of movement disorders
  • Huntington disease
  • Cognition in Parkinson's disease
Google Map

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to Listings go back five years.

  1. Therapeutic advances in Huntington's Disease.
    Shannon KM, Fraint A
    Mov. Disord.
    2015 Sep 15
  2. Colonic bacterial composition in Parkinson's disease.
    Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, Mutlu E, Shannon KM
    Mov. Disord.
    2015 Sep
  3. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.
    , Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, Augustine AH, Augustine EU, Aminoff MJ, Bodis-Wollner IG, Boyd J, Cambi F, Chou K, Christine CW, Cines M, Dahodwala N, Derwent L, Dewey RB, Hawthorne K, Houghton DJ, Kamp C, Leehey M, Lew MF, Liang GS, Luo ST, Mari Z, Morgan JC, Parashos S, Pérez A, Petrovitch H, Rajan S, Reichwein S, Roth JT, Schneider JS, Shannon KM, Simon DK, Simuni T, Singer C, Sudarsky L, Tanner CM, Umeh CC, Williams K, Wills AM
    2015 Feb 10
  4. Abnormal lipopolysaccharide binding protein as marker of gastrointestinal inflammation in Parkinson disease.
    Pal GD, Shaikh M, Forsyth CB, Ouyang B, Keshavarzian A, Shannon KM
    Front Neurosci
  5. Gut feelings about smoking and coffee in Parkinson's disease.
    Derkinderen P, Shannon KM, Brundin P
    Mov. Disord.
    2014 Apr 21
  6. Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease.
    Kelly LP, Carvey PM, Keshavarzian A, Shannon KM, Shaikh M, Bakay RA, Kordower JH
    Mov. Disord.
    2013 Nov 4
  7. Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor.
    Prodoehl J, Li H, Planetta PJ, Goetz CG, Shannon KM, Tangonan R, Comella CL, Simuni T, Zhou XJ, Leurgans S, Corcos DM, Vaillancourt DE.
    Mov Disord. 2013
    2013 May 14. doi: 10.1002/mds.25491. [Epub ahead of print]
  8. Force control deficits in individuals with Parkinson's disease, multiple systems atrophy, and progressive supranuclear palsy.
    Neely KA, Planetta PJ, Prodoehl J, Corcos DM, Comella CL, Goetz CG, Shannon KL, Vaillancourt DE.
    PLoS One. 2013
    8(3):e58403. doi: 10.1371/journal.pone.0058403. Epub 2013 Mar 11.
  9. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases.
    Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH.
    Mov Disord. 2012
    2012 May
    27(6):716-9. doi: 10.1002/mds.25020. Epub 2012 May 1.
  10. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease.
    Shannon KM, Keshavarzian A, Mutlu E, Dodiya HB, Daian D, Jaglin JA, Kordower JH.
    Mov Disord. 2012
    2012 May
    27(6):709-15. doi: 10.1002/mds.23838. Epub 2011 Jul 15.
  11. Suicidal ideation in Huntington disease: the role of comorbidity.
    Wetzel HH, Gehl CR, Dellefave-Castillo L, Schiffman JF, Shannon KM, Paulsen JS; Huntington Study Group.
    Psychiatry Res. 2011
    2011 Aug 15
    188(3):372-6. doi: 10.1016/j.psychres.2011.05.006. Epub 2011 May 24.
  12. Huntington's disease - clinical signs, symptoms, presymptomatic diagnosis, and diagnosis.
    Shannon KM.
    Handb Clin Neurol. 2011
    100:3-13. doi: 10.1016/B978-0-444-52014-2.00001-X. Review.
  13. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease.
    Forsyth CB, Shannon KM, Kordower JH, Voigt RM, Shaikh M, Jaglin JA, Estes JD, Dodiya HB, Keshavarzian A.
    PLoS One. 2011
    6(12):e28032. doi: 10.1371/journal.pone.0028032. Epub 2011 Dec 1.
  14. The Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in Huntington's disease.
    Videnovic A, Bernard B, Fan W, Jaglin J, Leurgans S, Shannon KM.
    Mov Disord. 2010
    2010 Feb 15
    25(3):401-4. doi: 10.1002/mds.22748.
  15. Daytime somnolence and nocturnal sleep disturbances in Huntington disease.
    Videnovic A, Leurgans S, Fan W, Jaglin J, Shannon KM.
    Parkinsonism Relat Disord. 2009
    2009 Jul
    15(6):471-4. doi: 10.1016/j.parkreldis.2008.10.002. Epub 2008 Nov 28.
  16. Long-term outcome in Parkinson disease: no advantage to initiating therapy with dopamine agonists.
    Shannon KM.
    Nat Clin Pract Neurol. 2008
    2008 Nov
    4(11):590-1. doi: 10.1038/ncpneuro0934. Epub 2008 Oct 14.
  17. The current clinical management of Huntington's disease.
    Phillips W, Shannon KM, Barker RA.
    Mov Disord. 2008
    2008 Aug 15
    23(11):1491-504. doi: 10.1002/mds.21971. Review.
  • (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
  • View Transcript
Patient feedback information is available for physicians employed by Rush University Medical Center who have received 30 or more patient surveys. Responses are measured on a scale of 1 to 5, with 5 being the best score.
Number of Patient Surveys
Friendliness/courtesy of the care provider
Explanations the care provider gave you about your problem or condition
Concern the care provider showed for your questions or worries
Likelihood of your recommending this care provider to others
Care provider's efforts to include you in decisions about your treatment
Information the care provider gave you about medications
Instructions the care provider gave you about follow-up care
Your confidence in this care provider
Degree to which care provider talked with you using words you could understand
Amount of time the care provider spent with you
For more information about patient feedback, see the Quality Care section of the Rush University Medical Center website.